Epiontis
Berlin
About Epiontis
Epiontis was founded in 2003 by Dr. Sven Olek and Dr. Ulrich Hoffmueller. The company is headquartered in the Science- and Technology Park Adlershof in the south of Berlin, Germany - a leading site for Biotechnology and Life Sciences in Berlin-Brandenburg. Epiontis offers worldwide services. Using a novel molecular diagnostics technology, Epiontis offers an immune cell monitoring service as well as customized development of epigenetic assays. Epiontis' epigenetic assay format allows the identification and quantification of any cell type with accuracy and technical ease. The main field of use is the monitoring of immune cells in research and clinical studies for autoimmune and infectious diseases or cancer. Here, they offer a portfolio of established assays for immune cells. Examples include diagnostic assays for regulatory T cells (Tregs) and tumor infiltrating lymphocytes, with many other epigenetic assays under development. In addition, they develop customized immunmonitoring essays that serve your needs.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Funding stage: M&A
- Last round: Undisclosed (Apr 2007)
- Website: epiontis.com
- Phone: +49-30-6392 3470
Industries & Categories
Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/epiontis-712787 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.